- Advertise
- Contact Us
- Editorial Info
- Contribute
- Terms and Conditions
- Privacy Policy
- Do not sell my Personal Information
© 2022 MJH Life Sciences™ and Rheumatology Network. All rights reserved.
Juvenile Arthritis
Secukinumab Delays Disease Flare in Pediatric Patients with Arthritis
August 16, 2022
Although the current treatment strategies for children with juvenile idiopathic arthritis help to relieve pain symptoms, these medications provide limited efficacy on the underlying disease.
Which Factors Impact Quality of Life for Families of Children with Juvenile Arthritis?
July 26, 2022
“Qualitative research has identified that caregivers face many challenges that affect their well-being, including balancing their child’s demands with their own psychological needs when feeling depressed or stressed, and accompanying the child to the frequent health appointments.”
Obesity Increases Risk of COVID-19 Hospitalization in Juvenile Patients
July 21, 2022
“Understanding the impact of COVID-19 infection on children and young people with RMDs is important to inform national protection, education (such as school attendance), and vaccination guidance."
Emotional Stressors May Trigger PFAPA Attacks in Pediatric Patients
July 14, 2022
“These results show that emotional distress is associated with higher frequency of PFAPA attacks, thus may be considered as an environmental trigger for PFAPA attack," investigators stated.
Is There a Link Between Maternal Infection and Juvenile Idiopathic Arthritis?
July 06, 2022
Previous attempts to make associations between JIA and prenatal maternal infection is difficult due to the rarity of JIA diagnosis and recall bias.
Secukinumab Receives Expanded Approvals in EU for Pediatric Arthritic Conditions
June 27, 2022
The approvals were based on results from the JUNIPERA trial, which showed secukinumab reduced the risk of flare and disease activity when compared with placebo over 2 years in pediatric patients with ERA and JPsA.
Baricitinib Effectively Reduces Frequency of Flares in Patients with JIA
June 15, 2022
The study, which assessed data from the JUVE-BASIS trial, suggests baricitinib significantly reduced both the time to and frequency of flares in patients with JIA when compared with placebo.
Secukinumab Receives Positive CHMP Opinion for Expansion in Childhood Arthritic Conditions
May 20, 2022
The Committee for Medicinal Products for Human Use (CHMP) issues a positive opinion to expand Novartis secukinumab indication to enthesitis-related arthritis (ERA) and juvenile psoriatic arthritis (JPsA).
Janet E McDonagh, MD, FRCP: Juvenile Idiopathic Arthritis Age Delays in Rheumatological Care
May 06, 2022
Janet E McDonagh, MD, FRCP, discusses the study “The Role of Age in Delays to Rheumatological Care in Juvenile Idiopathic Arthritis.”
Celiac Disease More Prevalent in Patients With Juvenile Idiopathic Arthritis
April 26, 2022
“Understanding the extent of the co-occurrence and identifying factors associated with an increased susceptibility could be relevant to implement case-finding strategies in specific at-risk populations," investigators stated.